Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Clinical Oncology Next-generation Sequencing Market is reaching a valuation of US$ 1.14 Billion by 2029 - Comprehensive Research Report by FMI

Clinical Oncology Next-generation Sequencing Market - Analysis, Outlook, Growth, Trends, Forecasts

DUBAI, United Arab Emirates, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The global Clinical Oncology Next-Generation Sequencing Market is estimated to be worth around US$ 449.4 Mn in 2022. With rising adoption of next generation sequencing (NGS) in clinical oncology for advance personalized treatment of cancer, the overall Clinical Oncology Next-Generation Sequencing Market is projected to expand at a prolific CAGR of 16.3% between 2022 and 2029, reaching a valuation of US$ 1.14 Bn by 2029.

Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing.

It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall Clinical Oncology Next-generation Sequencing Market.

Attribute

Details

Clinical Oncology Next-Generation Sequencing Market Estimated Size in 2022

US$ 449.4 Mn

Clinical Oncology Next-Generation Sequencing Market Projected Size in 2029

US$ 1.14 Bn

Clinical Oncology Next-Generation Sequencing Market Historical CAGR (2014-2021)

14.4%

Clinical Oncology Next-Generation Sequencing Market Value-Based CAGR (2022-2029)

16.3%

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value Share

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market.

Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the "sequencing by synthesis" principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which is also known as DNA sequencing.